However, though this supplementary analysis showed a trend in the point estimates of patients reaching the primary endpoint consistent with the efficacy hypothesis defined in the protocol, the sample of the intended target population was too small to draw an adequately powered conclusion regarding efficacy.
← all excerpts
Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial.
1
—
—